Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy: Results of an Updated Analysis

Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy: Results of an Updated Analysis

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Lorenzo Mantovani, Paolo Angelo Cortesi, Michele Molina, Laura Santoni, Luca Prosperini
التنسيق:	مقال
اللغة:	English
منشور في:	SEEd Medical Publishers 2024-12-01
سلاسل:	Farmeconomia: Health Economics and Therapeutic Pathways
الوصول للمادة أونلاين:	https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1568

مواد مشابهة

Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy
حسب: Lorenzo Giovanni Mantovani, وآخرون
منشور في: (2022-02-01)

Cost-Effectiveness Analysis of Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis: An Italian Societal Perspective
حسب: Lorenzo Giovanni Mantovani, وآخرون
منشور في: (2019-07-01)

[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]
حسب: Gianluca Furneri, وآخرون
منشور في: (2016-06-01)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
حسب: Nasim Nehzat, وآخرون
منشور في: (2021-01-01)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
حسب: Emanuele D’Amico, وآخرون
منشور في: (2018-09-01)

Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
حسب: Roberto Bomprezzi
منشور في: (2015-01-01)

Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
حسب: Silvia Boullosa-Lale, وآخرون
منشور في: (2021-03-01)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
حسب: Ozel O, وآخرون
منشور في: (2019-12-01)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
حسب: Boris A. Kallmann, وآخرون
منشور في: (2021-05-01)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
حسب: Bayas A, وآخرون
منشور في: (2015-02-01)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
حسب: Gianluca Furneri, وآخرون
منشور في: (2019-06-01)

Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain
حسب: Ricardo Ginestal, وآخرون
منشور في: (2023-01-01)

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
حسب: Karl E. Carlström, وآخرون
منشور في: (2019-07-01)

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
حسب: Raed Alroughani, وآخرون
منشور في: (2021-01-01)

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
حسب: Greene N, وآخرون
منشور في: (2022-12-01)

Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing–remitting multiple sclerosis
حسب: Ruggieri S, وآخرون
منشور في: (2014-03-01)

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
حسب: Lilyana Amezcua, وآخرون
منشور في: (2023-04-01)

Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
حسب: Narapureddy B, وآخرون
منشور في: (2019-10-01)

Case Report: Baló's Concentric Sclerosis-Like Lesion in a Patient With Relapsing-Remitting Multiple Sclerosis Treated With Dimethyl Fumarate
حسب: Karolina Kania, وآخرون
منشور في: (2022-05-01)

Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study
حسب: M.L. Martínez-Ginés, وآخرون
منشور في: (2023-10-01)

Real-world data on the effectiveness and safety of teriflunomide in patients with relapsing–remitting multiple sclerosis: The EFFECT study
حسب: Mª.C. Durán Herrera, وآخرون
منشور في: (2022-07-01)

Relapsing–Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment
حسب: Vanesa Cunill, وآخرون
منشور في: (2018-05-01)

[Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]
حسب: Lorenzo Giovanni Mantovani, وآخرون
منشور في: (2017-12-01)

Analysis of medication persistence and reasons for discontinuation of treatment with teriflunomide and dimethyl fumarate in a hospital series of patients with multiple sclerosis
حسب: D.A. García Estévez, وآخرون
منشور في: (2022-07-01)

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
حسب: Michelle Allan, وآخرون
منشور في: (2019-12-01)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
حسب: Kunio Nakamura, وآخرون
منشور في: (2022-03-01)

An update of teriflunomide for treatment of multiple sclerosis
حسب: Oh J, وآخرون
منشور في: (2013-04-01)

Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data
حسب: Steve Vucic, وآخرون
منشور في: (2022-08-01)

TERIFLUNOMIDE - A NEW TABLETED DRUG FOR THERAPY OF REMITTING DISSEMINATED SCLEROSIS (REVIEW)
حسب: E. V. POPOVA, وآخرون
منشور في: (2016-12-01)

Some risk management issues in teriflunomide treatment of patients with remitting multiple sclerosis
حسب: N. Y. Lasch
منشور في: (2015-12-01)

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
حسب: José E. Meca-Lallana, وآخرون
منشور في: (2023-10-01)

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE
حسب: Ralf Gold, وآخرون
منشور في: (2020-05-01)

The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy
حسب: Sanja Stanisic, وآخرون
منشور في: (2019-04-01)

Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
حسب: Diego Centonze, وآخرون
منشور في: (2018-11-01)

TEC-ADHERE: Real-World Persistence and Adherence on Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis in the French OroSEP Patient-Support Program
حسب: Pierre Labauge, وآخرون
منشور في: (2024-11-01)

Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE, CONFIRM, and ENDORSE”
منشور في: (2020-10-01)

A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries
حسب: Takahiko Saida, وآخرون
منشور في: (2019-01-01)

Humoral and Cellular Immunity After Vaccination Against SARS-CoV-2 in Relapsing-Remitting Multiple Sclerosis Patients Treated with Interferon Beta and Dimethyl Fumarate
حسب: Marcin Bazylewicz, وآخرون
منشور في: (2025-01-01)

[Budget impact analysis for peginterferon beta-1a in relapsing remitting multiple sclerosis in Italy]
حسب: Sergio Iannazzo, وآخرون
منشور في: (2016-07-01)

Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria
حسب: Michael Guger, وآخرون
منشور في: (2022-06-01)